Last reviewed · How we verify
NCT06626477: A-SS-001
Intra-Nasal Mechanical Stimulation (INMEST) as a Potential Treatment Method for Sjogren's Syndrome (SS)
NA trial testing Intra nasal mechanical stimulation treatment (INMEST) in Sjogren Syndrome in 26 participants. Completed in 19 July 2025.
19 July 2025
Quick facts
| Lead sponsor | Abilion Medical Systems AB |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 26 |
| Start date | 5 November 2024 |
| Primary completion | 19 July 2025 |
| Estimated completion | 19 July 2025 |
| Sites | 1 location across Sweden |
Drugs / interventions tested
- Intra nasal mechanical stimulation treatment (INMEST)
- Sham (No Treatment) — full drug profile →
Conditions studied
- Sjogren Syndrome — all drugs for Sjogren Syndrome →
Sponsor
Abilion Medical Systems AB — full company profile →
Who can join
18 and older, any sex, with Sjogren Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of the study is to investigate the effect and safety of the Walther System delivering INMEST (intranasal mechanical stimulation) on people with Sjogren\'s syndrome. A total of 30 subjects are planned to be enrolled and randomized to either use an active device or a sham device for the first 6 weeks. During the last 6 weeks all subjects will receive active treatment. The treatments are self-administered by the subject at home, three times a week and 10 minutes per nostril. Subjects will: * Use an active or sham device at home 3 times per week for six weeks. * All subjects will then get an active device for use another six weeks. * Visit the clinic every third week for measurements and checkups. * Keep a diary of the treatments and potential problems.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06626477
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Sjogren Syndrome
Currently open trials in the same condition.
- NCT07153276 — TREATMENT OF VAGINAL DRYNESS IN SJÖGREN'S DISEASE WITH CO2-LASER VERSUS TOPICAL PROMESTRIENE · Phase 4 · recruiting
- NCT06828042 — Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases · Phase 1, PHASE2 · recruiting
- NCT06794008 — BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases · Phase 2 · recruiting
- NCT06931041 — Comparing Efficacy of Autologous Serum Eye Drops With and Without Insulin in Autoimmune Dry Eye: A Randomized Clinical T · Phase 3 · active not recruiting
- NCT05349214 — Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome · Phase 3 · active not recruiting
Other Abilion Medical Systems AB trials
Trials by the same sponsor.
- NCT05887336 — Intra-Nasal Mechanical Stimulation (INMEST) As a Treatment Method for the Relief of Symptoms of Dry Eye · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06626477 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Abilion Medical Systems AB
- Last refreshed: 3 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06626477.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing